significantclinical trial result
ASPEN trial final analysis: zanubrutinib vs ibrutinib in WM
Waldenström's Macroglobulinemia →Summary
Final analysis of the phase 3 ASPEN trial (Tam et al., JCO 2023) at 44.4-month median follow-up confirmed zanubrutinib superiority in tolerability over ibrutinib with VGPR+CR rates of 36.3% vs 25.3%. Zanubrutinib had significantly lower rates of atrial fibrillation (7.9% vs 23.5%), hypertension, and diarrhea. Both agents showed high overall response rates. Results support zanubrutinib as preferred covalent BTK inhibitor in WM.
Related treatments
More from Waldenström's Macroglobulinemia
incrementalTreatment update
Emerging CAR-T and bispecific antibody approaches for WM
incrementalNew research
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
significantTreatment update
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
incrementalNew research
Genomics-guided treatment selection advances in WM
ID: waldenstroms-macroglobulinemia-update-0Type: clinical_trial_resultImpact: significant